PODD Insulet Corporation

Insulet Corporation to Present at Upcoming Investor Conference

Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management will present at the William Blair & Co. 37th Annual Growth Stock Conference in Chicago, Illinois on Tuesday, June 13, 2017 at 12:50 p.m. (Central Time).

To listen to a live audio webcast of the presentation, please visit http://investors.insulet.com. A replay of the webcast will also be available following the event.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its Omnipod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The Omnipod is a revolutionary and easy-to-use tubeless insulin pump that provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's Delivery Systems business also partners with global pharmaceutical and biotechnology companies to adapt the Omnipod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts. For more information, please visit: http://www.myomnipod.com.

EN
05/06/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Insulet Corporation

Research Team ACF
  • Research Team ACF

KDST + NLSP Combined Core Investment Case 29052025

We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...

Moody's Ratings upgrades Insulet's CFR to Ba3; outlook remains positiv...

Moody's Ratings (Moody's) upgraded Insulet Corporation's ("Insulet") Corporate Family Rating (CFR) to Ba3 from B1 and Probability of Default Rating ("PDR") to Ba3-PD from B1-PD. Concurrently, we affirmed the Ba2 rating on Insulet's senior secured term loan and assigned a Ba2 rating to Insulet's new ...

Research Team ACF
  • Research Team ACF

ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...

Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...

Insulet Corporation: Update to credit analysis following CFR upgrade

Our credit view of this issuer reflects its strong competitive position, but single product line focus.

Moody's Ratings upgrades Insulet's CFR to B1; outlook remains positive

Moody's Ratings (Moody's) upgraded Insulet Corporation's ("Insulet") Corporate Family Rating (CFR) to B1 from B2 and Probability of Default Rating ("PDR") to B1-PD from B2-PD. Concurrently, we affirmed the Ba2 ratings on Insulet's senior secured credit facilities, including the senior secured term l...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch